Judicious Use of Immunomodulatory Agents to Manage Noninfectious Uveitis
Judicious Use of Immunomodulatory Agents to Manage Noninfectious Uveitis
Mohamed Ibrahim, MD • Mostafa Hannout, MB BCh • Yasir Sepah, MBBS • Elham Hatef, MD • Jangwon Heo, MD • Jeong Hee Lee, MD • Ovais Shaikh, MD • Roomasa Channa, MD • Afsheen Khwaja, MD • Quan Dong Nguyen, MD, MSc
Uveitis is a leading cause of blindness in the developed world, affecting approximately 0.2% of individuals and accounting for 10% to 20% of cases of legal blindness.1-2 The etiologies of uveitis and ocular inflammatory diseases are protean; infectious causes and masquerade syndromes (often for an underlying malignancy) need to be considered in appropriate cases. In the United States, many cases of uveitis are judged to be autoimmune in nature.3 Early diagnosis and treatment are important to prevent the vision-threatening complications of uveitis, such as glaucoma, retinopathy and macular edema.4
The standard of care for noninfectious uveitis is local, topical and oral corticosteroids (CS). These are currently the only drugs approved by the FDA to treat noninfectious uveitis.2,5 The primary goal of therapy is to suppress inflammation and achieve remission when the disease exacerbates.6,7 Although CSs are effective in achieving this primary goal, they often cause significant morbidity and sometimes mortality. All types of CSs, through different modes of deliveries, are associated with adverse effects (AEs) ranging from local effects such as glaucoma, cataract and scleral melting to potentially dangerous complications such as diabetes, congestive heart failure, osteoporosis and Cushing's syndrome. A correlation has been observed between high doses of CS and increased risk of side effects.8 The morbidities caused by CSs warranted the development in 2000 by an expert panel of treatment guidelines that were reinforced by the Standardization of Uveitis Nomenclature Working Group in 2005.9,10 To decrease the risk of serious AEs associated with systemic long-term CS use, current guidelines recommend the addition of immunomodulatory therapeutic (IMT) agents if inflammation cannot be controlled with <10 mg/day of prednisone (or equivalent) within three months.9,10
However, IMT agents have their own risks, especially if they are not used wisely and properly. IMT can be extremely dangerous and harmful to patients. Therefore, judicious use of IMT requires careful assessment of the patient's health and assessing and understanding the nature of the inflammatory condition at hand, as well as consideration of the condition's severity, careful selection of the IMT agent and treatment regimen and, finally, careful and continuous monitoring of the therapy throughout the entire course, and sometimes after discontinuation, of IMT.
Antimetabolites, calcineurin inhibitors, alkylating agents and, most recently, biologic response modifiers are used as IMT, steroid-sparing agents in noninfectious uveitis. We herein discuss very briefly some of the commonly used IMT agents in the management of uveitis and ocular inflammatory diseases.
Antimetabolites are chemicals that inhibit metabolites, which are parts of normal cellular metabolism. The use of antimetabolites results in interference with normal cell function, especially cell growth and proliferation. Rapidly proliferating cells, eg, T- and B-lymphocytes, are vulnerable to such effect, which accounts for the bioactivity of anti-metabolites in the treatment of immunologic diseases including uveitis.
Methotrexate. Methotrexate is an antifolate agent that competitively inhibits dihydrofolate reductase, thus inhibiting thymidine synthesis, and hence interferes with DNA replication and cellular proliferation.10 Use of methotrexate in uveitis has been described since 1966.11 Serious AEs include reversible hepatotoxicity with abnormal liver function tests; approximately 0.1% of patients treated with methotrexate develop hepatic cirrhosis. Interstitial hypersensitivity pneumonitis may occur either early or late in treatment.12 The favorable safety profile of methotrexate, along with the convenience of its weekly administration, have made it a popular steroid-sparing agent in children and adults.
Azathioprine. A purine analog that inhibits DNA replication and RNA transcription, azathioprine suppresses proliferation of T- and B-lymphocytes and reduces mixed lymphocyte reactivity, interleukin-2 synthesis and IgM production.10 Azathioprine has been shown to be effective in treating sympathetic ophthalmia, Adamantiades-Behçet disease (ABD), Vogt-Koyanagi-Harada (VKH) syndrome, and serpiginous choroidopathy — particularly in combination with steroids or other IMT agents.13
Serious AEs of azathioprine include reversible myelo-suppression (25%) and reversible hepatotoxicity with elevated LFTs.13 Azathioprine is nonenzymatically converted in vivo to the active metabolites 6-mercaptopurine (90%) and 6-thioinosinic acid (10%).14 The enzyme thiopurine S-methyltransferase (TPMT) deactivates 6-mercaptopurine. Low activity of TPMT leads to toxicity effects. Therefore, assessment of the serum levels of TPMT at baseline may help to decrease the risk of developing azathioprine toxicity.11 Elevated hepatic enzymes — with AST or ALT more than 1.5x the upper limit of normal values — requires reduction of the dosage. Significant elevations mandate discontinuation of azathioprine.
Mycophenolate mofetil. MMF is a prodrug that selectively inhibits the inosine monophosphate dehydrogenase enzyme and thus inhibits the de novo pathway of purine synthesis. MMF prevents the proliferation of B- and T-lymphocytes, suppresses antibody synthesis, interferes with cellular adhesion to the vascular endothelium and decreases recruitment of leukocytes to sites of inflammation.10 MMF is generally well tolerated; however, uncommon severe toxicities may occur, including leukopenia, opportunistic infections, viral infections (eg, CMV and HSV), hepatotoxicity and lymphoma. The favorable safety profile of MMF, especially the lower risks of myelosuppression and opportunistic infections, has encouraged its use in place of azathioprine in organ transplantation and uveitis.15 MMF is increasingly used as a steroid-sparing agent in the management of a variety of inflammatory ocular diseases, including VKH, sympathetic ophthalmia, birdshot retinochoroidopathy, ABD, serpiginous choroidopathy and scleritis.
Activation of the T-cell receptors normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. The activated calcineurin upregulates expression of interleukin 2 (IL-2), which in turn stimulates T-cell growth and differentiation. Blockage of calcineurin results in inhibition of T-lymphocyte proliferation, adhesion and recruitment. Calcineurin inhibitors act by forming a complex through binding to the cytosolic protein immunophilin. Such a complex subsequently inhibits calcineurin. Calcineurin is normally responsible for activation of the transcription factor NF-AT, which in turn increases transcription of IL-2 and other cytokines. IL-2 binds to T-cells and promotes proliferation and further cytokine release. Thus when calcineurin is inhibited, T-cell proliferation and release of proinflammatory cytokines are subsequently blocked.
Cyclosporine A. CsA binds to intracellular immunophilin receptors (cyclophilin), leading to reversible blockage of calcineurin activation. Thus, it inhibits production of IL-2 and related cytokines.14 CsA has been found in therapeutic levels in the intraocular fluids of uveitis patients.16 The most significant AEs include reversible nephrotoxicity and hypertension. Less common side effects include gingival hyperplasia, myalgias, hepatotoxicity, tremor and paresthesia.17
Tacrolimus. A macrolide antibiotic that has been described and used in uveitis since 1991,14 tacrolimus interferes with proliferation of CD4+ T-lymphocytes in a mechanism similar to CsA through binding to intracellular immunophilin receptors. Tacrolimus, however, is 10 to 30 times more potent than CsA. Such potency is particularly useful when treating sight-threatening uveitis, especially when the uveitis is refractory to CsA or when the AEs of CsA are unacceptable.14 Tacrolimus has demonstrated long-term efficacy in controlling ABD, intermediate and posterior uveitis, and uveitis refractory to CsA.18-23 The most important side effects include dose-dependent renal impairment, neurological symptoms, gastrointestinal symptoms, hyperglycemia, dizziness and headache.24
Alkylating agents are the most potent immunomodulatory agents available. However, they also have the most potential for significant toxicity. Thus, they are usually reserved for severe sight-threatening uveitis.
Alkylating agents are alkylate nucleic acids resulting in DNA-to-DNA and DNA-to-protein cross-linking. DNA cross-linking interferes with DNA replication and RNA transcription, resulting in cell death. These agents are cytotoxic to both resting and dividing lymphocytes, resulting in reduction of T- and B-lymphocytes in peripheral blood and suppression of T-helper cells and cytokines production.14
Cyclophosphamide. Phosphoramide mustard is the active metabolite of cyclophosphamide (CP). Aldehyde dehydrogenase (ALDH) detoxifies cyclophosphamide through interference with the phosphoramide mustard formation. Highly proliferating cells, such as bone marrow, liver and intestinal epithelium, have a high concentration of ALDH; this confers some level of tolerance to cyclophosphamide against the typical toxic effects of alkylating agents. CP is immunosuppressant and cytotoxic only in high doses.
Many clinicians titrate CP dose to obtain a leukocyte count of 3,000-4,000 cells/mL, after discontinuation of oral corticosteroid therapy; it is thought that this level of immunosuppression is associated with better long-term inflammatory control and ability to achieve disease remission.25
A common serious AE of cyclophosphamide is hemorrhagic cystitis, which can be avoided through adequate fluid intake (> 2L/day). One of CP's metabolites, acrolein, is thought to be responsible for the urologic toxicity. The use of 2-mercaptoethane sulfonate may detoxify acrolein.10 Increased risk of bladder cancer, myelosuppression, sterility and opportunistic infections are also serious AEs of CP.
Chlorambucil. A nitrogen mustard, chlorambucil is an alkylating agent that is mainly used in treatment of chronic lymphocytic leukemia (CLL). It is also used in treating other malignancies, including various types of non-Hodgkin's lymphoma and Waldenström macroglobulinemia. Chlorambucil is also used in management of auto-immune and inflammatory conditions, such as nephrotic syndrome, and hematological conditions, such as polycythemia vera. Although well tolerated, chlorambucil has largely been replaced by fludarabine in treatment of young patients with CLL.
Chlorambucil has been used in selected cases of uveitis and ocular inflammatory diseases, although its effectiveness may be less predictable than cyclophosphamide. Anemia and thrombocytopenia are common with chlorambucil. Also, in addition to serious AEs similar to those associated with cyclophosphamide, chlorambucil can cause peripheral neuropathy, seizures (in children with nephrotic syndrome), hallucinations and hepatotoxicity.
BIOLOGIC RESPONSE MODIFIERS
Biologics are medicinal products created through biological processes. Those in use for management of noninfectious uveitis either target regulating cytokines that mediate the immune response (cytokine blockers) or target cellular receptors of specific immune cells (receptor blockers).
Most cytokine blockers used in uveitis target tumor necrosis factor (TNF)-α, a proinflammatory cytokine. However, recent studies have demonstrated a potential role of interferon-α 2-α. TNF-α is produced in response to inflammation, infection, and other environmental stresses. Most cells express TNFR1 (tumor necrosis factor receptor 1), which is believed to be the major mediator of the cytotoxicity of TNF-α.26 TNF-α holds a very important role in the inflammatory cascade, which accounts for the powerful effect of TNF-α blockers in controlling the inflammatory process. The role of T-cell activation and TNF-α production in uveitis in humans has also been demonstrated.27,28
Infliximab. A chimeric monoclonal antibody (mAb) composed of human-murine sequences, infliximab has been used successfully in children with noninfectious uveitis, leading to maintenance of visual acuity, improved control of ocular inflammation and reduced reliance on corticosteroids.29 There are also excellent results reported in adults with ABD and other causes of posterior uveitis and scleritis.30 In Japan, recent studies have supported the use of infliximab as first-line therapy for ABD. Serious AEs include myelosuppression, demyelinating neurological disorders (eg, multiple sclerosis), infectious diseases, activation of latent infections (TB and HBV), malignancies and immunological disorders, such as drug-induced SLE and immune hypersensitivity reactions.
Adalimumab is a fully human mAb that targets TNF-α. Being fully humanized and having a subcutaneous route of administration are clear advantages of adalimumab when compared to infliximab. Several reports have demonstrated a successful use of adalimumab in management of ABD, severe forms of VKH syndrome, JRA-associated uveitis and idiopathic pediatric uveitis.31-35 The most common side effect associated with adalimumab is injection-site reaction (10%). It is relatively safe and tolerable with rare serious AEs, including serious infections, lymphoma, tuberculosis, herpetic keratitis, opportunistic infections, demyelinating diseases, drug-induced SLE, elevated hepatic enzymes and congestive heart failure.6
Etanercept is a genetically engineered fusion protein of TNF receptor p75. There have been few case series reporting successful use of etanercept in uveitis.36 Other trials reported no difference in inflammatory indices between groups treated with etanercept and placebo in patients with juvenile idiopathic arthritis (JIA)-associated uveitis.37 In other trials, etanercept did not appear to protect against the onset,38 nor relapses, of uveitis.39 When compared with infliximab in the treatment of uveitis, etanercept has repeatedly been found to be inferior.40 Given its low efficacy, etanercept is not currently being used often in management of uveitis and ocular inflammatory disease.
Interferon α-2a is an immunomodulating cytokine with antiviral, antiproliferative and antiangiogenic properties. It has been commonly used in the treatment of hepatitis C, myeloproliferative diseases and lymphomas.41 Several studies have reported successful short- and long-term use, as well as steroid-sparing effect, of interferon α-2a in ocular ABD42-46 and chronic posterior uveitis refractory to conventional treatment.1,41,47 Other case series have reported promising results in MS-related intermediate uveitis and in serpiginous choroiditis.48
Systemic AEs are flu-like symptoms, mild leukopenia and alopecia. Less common but serious side effects include CNS effects (depression, confusion, seizures and psychosis), autoantibodies (antithyroid), thrombocytopenia, hypotension and elevated liver enzymes.
Cell Receptor Blockers
Specific cell receptors are being targeted through specially designed recombinant mAb. Interleukin receptors are the main targets for these mAb in noninfectious uveitis.
Daclizumab is a recombinant mAb composed of human-murine IgG-1 sequences that targets interleukin-2 (IL-2) receptors of activated T- and B-lymphocytes,49,50 consequently inhibiting the IL-2 signaling pathway. One trial found no benefits of daclizumab in treating posterior inflammation associated with ABD.51 Another found that daclizumab allowed control of inflammation with low-dose corticosteroids or other immunosuppressive agents in intermediate and posterior uveitis.17 Serious side effects reported with daclizumab use were rare; however, it has been discontinued in the United States. According to the manufacturer, this decision was based on the availability of alternative treatments and the diminishing market demand.52
Anakinra. A recombinant human mAb targeting the interleukin 1 (IL-1) receptors, anakinra downregulates the IL-1-mediated immune response through competitive inhibition of IL-1 receptors of T- and B-lymphocytes and NK cells. Teoh et al. reported a successful use of anakinra in a four-year-old boy with posterior uveitis associated with CINCA (chronic infantile neurological, cutaneous, and articular) syndrome. Similarly, Dinarello et al. reported another successful use in 75-year-old female with ABD refractory to other treatments including infliximab.53,54
Rare, serious AEs have been reported in association with anakinra, including bacterial cellulitis, neutropenia, serious infections and malignancies (melanoma, lymphoma and breast cancer).
AGENTS IN DEVELOPMENT FOR UVEITIS AND OCULAR INFLAMMATORY DISEASES
Voclosporin. This novel calcineurin inhibitor is more similar to CsA than to a single functional group. Voclosporin is currently being developed with indications for prevention of organ graft rejection and treatment of auto-immune diseases, such as psoriasis. It has also been evaluated in phase 3 studies for use in noninfectious uveitis and has been found to be four times more potent than CsA in in vitro and in vivo studies. The adverse events of voclosporin have been found to be much less than those of CsA. Results from early studies suggest that voclosporin has a more favorable safety profile as lower therapeutic doses can be used, and it has a higher bioavailability than CsA. Additional phase 3 studies of voclosporin in active, noninfectious, intermediate, posterior, or panuveitis are being conducted for approval by the FDA.
AIN457. The cytokine interleukin 17 (IL-17) is a protein produced by inflammatory cells that initiates, maintains, or augments the inflammatory response in certain conditions. The levels of IL-6, IL-17 and IL-18 are elevated in serum of patients with ABD. IL-17 mRNA levels in peripheral blood mononuclear cells are also elevated in some patients with uveitis. Thus far, IL-17 appears to play a role in the development or maintenance of uveitis.
Therapy with AIN457, an anti-IL-17 antibody given either systemically or via intravitreal injections, reduces inflammation in mouse models of uveitis. Studies of subcutaneous injections with AIN457 are currently being conducted in patients with uveitis who require steroid-sparing therapy, and this may provide information about the potential of this drug in the management of uveitis and ocular inflammatory diseases.
Sirolimus, also known as rapamycin, was isolated in the 1970s from Streptomyces hygroscopicus in soil samples from Easter Island. Sirolimus is the active pharmaceutical ingredient in two products approved by the FDA, specifically Rapamune, an immunosuppressive agent used in renal transplant patients, and the Cypher Sirolimus-eluting Coronary Stent, approved for improving coronary luminal diameter in patients with symptomatic ischemic disease.
The mechanism of action of sirolimus in immunosuppression has been described extensively in the literature. Sirolimus blocks T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4 and IL-15) stimulation, employing either Ca2+ dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase.
The inhibition of mTOR blocks IL-2-mediated signal transduction pathways that prevent cell cycle progression from G1 to S phase in T-cells, endothelial cells, osteosarcoma cells, myogenic cell lines and smooth muscle cells. In addition, sirolimus inhibits the production of antibodies. Sirolimus has also been shown to downregulate the expression of many genes related to inflammation, such as interleukin-8 and inducible nitric oxide synthase.
Sirolimus, administered systemically, has been used in selected cases of refractory posterior and panuveitis. Currently, local administration of sirolimus, either as subconjunctival or intravitreal injection, is being investigated as potential therapeutic options for noninfectious uveitis requiring IMT or steroid-sparing therapy. Such formulary may be very welcome if efficacy can be demonstrated and systemic adverse events can be eliminated or diminished significantly.
PRECAUTIONS WHEN EMPLOYING IMT
The expected insufficiency of CSs in controlling sight-threatening conditions (eg, ABD, sympathetic ophthalmia, VKH and necrotizing sclerouveitis) are clear indications for its early use of IMT. However, even in those cases where the success of CS therapy is expected, early use of IMT may be indicated either to improve the long-term prognosis or to avoid or reduce the long-term morbidities associated with CS. Intolerable side effects from CSs and chronic/relapsing diseases requiring long-term CS in doses > 10 mg per day are relative indications of IMT.
However, although the use of IMT is clearly indicated in many cases of noninfectious uveitis, for both safety and efficacy outcomes, before initiating IMT a clinician should rule out the presence of concurrent active or latent infections or hepatic and hematologic contraindications, and the physician should be aware of concomitant use of other IMT and interacting drugs. In addition, the treating physician should bring all patients up to date with their vaccinations, discuss with patients the risks associated with pregnancy and breast-feeding, and discuss family planning if alkylating agents are to be used.
Laboratory investigations should include complete blood count with differential and platelets, liver function tests, renal function tests, blood glucose level, lipids profile and electrolytes profile. Other specific measures should also be taken with certain agents, such as chest X-ray with anti-metabolites, TPMT levels with azathioprine, hepatitis Bs-Ag and hepatitis C-Ab with mycophenolate mofetil, and urinalysis with alkylating agents. Remind patients regularly to alert their primary care physician of their IMT agents and to report to their ocular immunologists/uveitis specialists any change in their concomitant medications to avoid potential toxicities that may result from drug interactions.
During therapy, close monitoring of the inflammatory indices and drug toxicity parameters should guide the dosage or possible discontinuation of the IMT agent. Remissions encourage reduction of dose mild or moderate toxicity may require reduction of dose and/or addition of other agents; and severe toxicities warrant discontinuation of the therapeutic agent. Laboratory investigations, such as CBC with differential and platelets, renal function tests, liver function tests, blood sugar, lipids profile and electrolyte profile, should be performed routinely every six to eight weeks to monitor potential IMT toxicities. Blood pressure should be monitored at every clinic visit, which should be every six to eight weeks, especially with calcineurin inhibitors; urinalysis every six to eight weeks with alkylating agents; chest X-ray every six months with antimetabolites; and plasma levels of cyclosporine every six months.
In addition to all the above-mentioned routine investigations, a major part of IMT monitoring requires the cooperation of patients in reporting any symptoms/signs that may suggest an IMT toxicity, especially infections, hematuria, delayed wound healing, cardiological manifestations such as congestive heart failure and arrhythmias, neurological manifestations such as seizures, paresthesia, myalgia and muscular weakness, and psychological symptoms such as hallucinations, insomnia, depression and suicidal/homicidal thoughts.
Clinician scientists caring for patients with uveitis and ocular inflammatory diseases should employ a no-tolerance policy toward any degree of inflammation. Recently, a survey study of ophthalmologists and rheumatologists in the United States who routinely manage patients with uveitis revealed very worrisome results: 75% of those surveyed were not familiar with or did not adhere to currently recommended guidelines for management of uveitis. High doses of corticosteroids (>10 mg of prednisone or equivalent) are still being used to maintain control of disease, and there is a low level of awareness of recommended guidelines to treat noninfectious uveitis.55 When IMT is employed properly and monitored appropriately, the potential adverse events are manageable and may be acceptable when benefits to patients can be demonstrated.14 The findings from the survey clearly underscore the need to educate the medical community and to reinforce treatment guidelines to improve the care of patients with uveitis. RP
1. Paire V, Lebreton O, Weber M. [Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment]. J Fr Ophtalmol 2010;33:152-62.
2. Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. British Journal of Ophthalmology 2008;92:455-459.
3. Gery I, Chan C. Mechamism of Uveitis. In: Yanoff M, Duker JS, editors. Yanoff & Duker: Opthalmology: Mosby, Inc., 2008.
4. Durrani OM, Meads CA, Murray PI. Uveitis: A potentially blinding disease. Ophthalmologica 2004;218:223-236.
5. Sobrin L, Christen W, Foster CS. Mycophenolate Mofetil after Methotrexate Failure or Intolerance in the Treatment of Scleritis and Uveitis. Ophthalmology 2008;115:1416-1421.e1.
6. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
7. Gupta R, Murray PI. Chronic non-infectious uveitis in the elderly: Epidemiology, pathophysiology and management. Drugs and Aging 2006;23:535-558.
8. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases 2009;68:1119-1124.
9. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. American Journal of Ophthalmology 2005; 140:509-516.
10. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immuno-suppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
11. Kurup SK, Chan CC. Immunotherapeutic approaches in ocular inflammatory diseases. Arch Immunol Ther Exp (Warsz) 2005;53:484-96.
12. Jabs DA. Treatment of ocular inflammation. Ocul Immunol Inflamm 2004; 12:163-8.
13. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322:281-5.
14. Habot-Wilner Z, Lightman S. Immunomodulatory Therapy in Uveitis. In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, editors. Retinal Pharmacotherapy: Saunders Elsevier Inc., 2010:248-258.
15. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9:1-179, iii-iv.
16. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36:25S-32S.
17. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-70.
18. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:1000-6.
19. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 2007;17:69-74.
20. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-41.
21. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106:723-8.
22. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998;6:101-9.
23. Sakane T, Mochizuki M, Inaba G, Masuda K. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet's disease and allied conditions]. Ryumachi 1995;35:802-13.
24. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115:763-9.
25. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology 1991;98:944-51; discussion 951-2.
26. Englaro W, Bahadoran P, Bertolotto C, et al. Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation. Oncogene 1999;18:1553.
27. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5.
28. Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol 2004; 88:412-6.
29. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-849.
30. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53.
31. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
32. Diaz Llopis M, Amselem L, Romero FJ, Garcia-Delpech S, Hernandez ML. [Adalimumab therapy for Vogt-Koyanagi-Harada syndrome]. Arch Soc Esp Oftalmol 2007;82:131-2.
33. Mansour AM. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:274-6.
34. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007;21:824-5.
35. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007; 66:565-6.
36. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 2003;48:2079-80.
37. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
38. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645-6.
39. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40.
40. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
41. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007; 144:55-61.
42. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006; 244:1692-5.
43. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9.
44. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007;46:1570-3.
45. Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010;62:2796-805.
46. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010;117:1430-5.
47. Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009;93:906-13.
48. Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005;89:1254-7.
49. Kanegane H, Miyawaki T, Kato K, et al. A novel subpopulation of CD45RA+ CD4+ T cells expressing IL-2 receptor alpha-chain (CD25) and having a functionally transitional nature into memory cells. Int Immunol 1991;3:1349-56.
50. Zola H, Weedon H, Thompson GR, Fung MC, Ingley E, Hapel AJ. Expression of IL-2 receptor p55 and p75 chains by human B lymphocytes: effects of activation and differentiation. Immunology 1991;72:167-73.
51. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007; 15:63-70.
52. Hoffmann-La-Roche. Dear Healthcare Professional Letter for ZENAPAX(R) (daclizumab): Hoffmann-La Roche Inc, 2009.
53. Dinarello CA. Resistant Behçet Disease Responsive to Anakinra: American College of Physicians, 2008:284-286.
54. Teoh SCB, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. British Journal of Ophthalmology 2007;91:263-264.
55. Nguyen QD, Hatef E, Kayen B, et al. A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States. Ophthalmology, in press. Available online August 3, 2010.
|Mohamed Ibrahim, MD, Yasir Sepah, MBBS, Elham Hatef, MD, Jangwon Heo, MD, Jeong Hee Lee, MD, Ovais Shaikh, MD, Roomasa Channa, MD, Afsheen Khwaja, MD, and Quan Dong Nguyen, MD, MSc, are all on the faculty of the Wilmer Eye Institute at Johns Hopkins University. Mostafa Hannout, MB BCh, practices at Shebin El-Kom Eye Hospital in Menoufia, Egypt. Dr. Nguyen reports research funding from Lux Biosciences, Novartis, MacuSight, Abbott and Santen; none of the other authors reports any financial interest in any products mentioned here. Dr. Nguyen can be reached at email@example.com.|
Retinal Physician, Issue: November 2010